EKR Therapeutics Approved for Intravenous Bags of Cardene Calcium Channel Blocker

 

August 4, 2008

August 4, 2008 - EKR Therapeutics Inc., said today it received FDA approval for Cardene I.V. (nicardipine hydrochloride) premixed injection, a patented, ready-to-use, single use intravenous bag for the administration of this calcium channel blocker.

The 200 ml RTU bags contain 20 mg of the anti-hypertensive agent nicardipine hydrochloride (0.1 mg/ml) in either dextrose or sodium chloride.

Based on data on file at EKR, more than 900,000 patients have been treated with Cardene I.V. since 2003.

For more information: www.ekrtx.com

The content of this field is kept private and will not be shown publicly.
Type the characters you see in this picture. (verify using audio)
Type the characters you see in the picture above; if you can't read them, submit the form and a new image will be generated. Not case sensitive.